In this network meta- analysis , we demonstrated that SeR did not show clinical ly meaningful improvement in LUTS and PF .
PATIENT SUMMARY In the present study , we found no clinical ly meaningful improvement of Serenoa repens for the treatment of lower urinary tract symptoms/benign prostatic enlargement .
CONTEXT International guidelines do not make any specific recommendations on Serenoa repens ( SeR ) for the treatment of male lower urinary tract symptoms ( LUTS ) secondary to benign prostatic enlargement ( BPE ) , due to product heterogeneity and method ological limitations of the published trials and meta-analyses .
OBJECTIVE We aim ed to compare the clinical efficacy of hexanic extract of SeR ( HESr ) versus non-HESr ( nHESr ) versus placebo versus alpha-blockers ( ABs ) in patients affected by LUTS secondary to BPE through a network meta- analysis method .
Efficacy and safety of once-daily alfuzosin in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a randomized, placebo-controlled trial.
OBJECTIVES To assess the efficacy and safety , and determine the optimal dosage , of a once-daily ( OD ) formulation of the clinical ly uroselective alpha(1)-blocker , alfuzosin , in patients with lower urinary tract symptoms and symptomatic benign prostatic hyperplasia . METHODS Five hundred thirty-six patients were r and omized to receive alfuzosin ( 10 mg OD or 15 mg OD ) , without initial dose titration , or placebo in a 3-month double-blind trial conducted in North America . The primary efficacy criteria were improvement in symptoms ( International Prostate Symptom Score ) and peak urinary flow rate . RESULTS Alfuzosin was significantly more effective than placebo in improving the symptoms and peak urinary flow rate from the first follow-up visit ( day 28 ) . The mean change in the International Prostate Symptom Score from baseline at endpoint was -3.6 and -3.4 with alfuzosin 10 mg and 15 mg , respectively , compared with -1.6 with placebo ( alfuzosin 10 mg versus placebo , P = 0.001 ; alfuzosin 15 mg versus placebo , P = 0.004 ) . The median increase in the peak urinary flow rate was + 1.1 mL/s and + 1.0 mL/s with alfuzosin 10 mg and 15 mg , respectively , compared with 0.0 mL/s with placebo ( P = 0.0006 versus placebo for both dose groups ) . The patients ' quality of life also significantly improved with both alfuzosin doses . Overall , alfuzosin at both doses was well tolerated . The incidence of orthostatic hypotension as determined by systematic blood pressure measurements with both doses of alfuzosin was similar to placebo . No clinical ly relevant ejaculation disorders were observed with alfuzosin . CONCLUSIONS Alfuzosin 10 mg OD , administered without dose titration , provides effective relief from the symptoms of benign prostatic hyperplasia with no additional benefit from a 15-mg dose . It is well tolerated from a cardiovascular viewpoint and is not associated with abnormal ejaculation
In this network meta- analysis , we demonstrated that SeR did not show clinical ly meaningful improvement in LUTS and PF .
PATIENT SUMMARY In the present study , we found no clinical ly meaningful improvement of Serenoa repens for the treatment of lower urinary tract symptoms/benign prostatic enlargement .
CONTEXT International guidelines do not make any specific recommendations on Serenoa repens ( SeR ) for the treatment of male lower urinary tract symptoms ( LUTS ) secondary to benign prostatic enlargement ( BPE ) , due to product heterogeneity and method ological limitations of the published trials and meta-analyses .
OBJECTIVE We aim ed to compare the clinical efficacy of hexanic extract of SeR ( HESr ) versus non-HESr ( nHESr ) versus placebo versus alpha-blockers ( ABs ) in patients affected by LUTS secondary to BPE through a network meta- analysis method .